Wall Street analysts expect Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) to announce $2.18 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Tetraphase Pharmaceuticals’ earnings, with the highest sales estimate coming in at $3.60 million and the lowest estimate coming in at $750,000.00. Tetraphase Pharmaceuticals posted sales of $11.58 million during the same quarter last year, which suggests a negative year-over-year growth rate of 81.2%. The company is scheduled to report its next earnings results on Thursday, August 1st.

According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year sales of $10.05 million for the current financial year, with estimates ranging from $4.10 million to $16.57 million. For the next fiscal year, analysts forecast that the business will report sales of $24.40 million, with estimates ranging from $10.50 million to $49.37 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Tetraphase Pharmaceuticals.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. Tetraphase Pharmaceuticals had a negative net margin of 383.19% and a negative return on equity of 80.01%. The firm had revenue of $1.27 million during the quarter, compared to analyst estimates of $1.93 million.

A number of research firms have commented on TTPH. Gabelli lowered shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.40 target price for the company. in a report on Friday, March 15th. Zacks Investment Research lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 20th. Piper Jaffray Companies lowered their target price on shares of Tetraphase Pharmaceuticals from $6.00 to $4.00 and set an “overweight” rating for the company in a report on Friday, March 15th. ValuEngine cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Tetraphase Pharmaceuticals in a research report on Monday, May 6th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $4.08.

TTPH opened at $0.88 on Thursday. The company has a debt-to-equity ratio of 0.53, a current ratio of 7.28 and a quick ratio of 7.10. Tetraphase Pharmaceuticals has a 52 week low of $0.86 and a 52 week high of $4.49. The firm has a market cap of $47.70 million, a price-to-earnings ratio of -0.64 and a beta of 2.85.

Several hedge funds and other institutional investors have recently made changes to their positions in TTPH. Paloma Partners Management Co bought a new position in shares of Tetraphase Pharmaceuticals during the fourth quarter worth $33,000. Gamco Investors INC. ET AL boosted its position in shares of Tetraphase Pharmaceuticals by 42.9% during the fourth quarter. Gamco Investors INC. ET AL now owns 50,000 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 15,000 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Tetraphase Pharmaceuticals during the fourth quarter worth $69,000. Rhumbline Advisers boosted its position in shares of Tetraphase Pharmaceuticals by 40.6% during the fourth quarter. Rhumbline Advisers now owns 72,976 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 21,089 shares in the last quarter. Finally, State of Wisconsin Investment Board boosted its position in shares of Tetraphase Pharmaceuticals by 29.8% during the first quarter. State of Wisconsin Investment Board now owns 71,000 shares of the biopharmaceutical company’s stock worth $95,000 after purchasing an additional 16,300 shares in the last quarter. 42.23% of the stock is currently owned by institutional investors.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Featured Story: Commodities

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.